A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Exclusion Criteria

• •Secondary forms of IgAN, as determined by the Investigator, diagnosis of IgA vasculitis, or any other nephropathy or chronic urinary tract disorder
• •Total IgG \<6.0 g/L at screening
• •Any chronic urinary tract disorder, including but not limited to retention, incontinence, and/or recurrent urinary tract infections
• •Untreated hypertension or uncontrolled hypertension despite treatment (i.e., resistant hypertension)
• •Treatment with complement pathway inhibitors, mycophenolic acids, systemic calcineurin inhibitors or corticosteroids, immunosuppressive or immunomodulatory agents within 12 months prior to screening
• •Acute kidney injury (AKI), defined by AKI network criteria, within 4 weeks prior to screening
• •Current treatment with anti-APRIL monoclonal antibodies or dual APRIL/BAFF inhibitors or past treatment of the same at any time for \>3 consecutive months prior to screening
• •Planned initiation of, or recently (within 24 weeks) initiated, treatment with glucagon-like peptide-1 agonists at screening